Peptides to Tackle Leishmaniasis: Current Status and Future Directions
Abstract
:1. Introduction
2. Peptides Targeting Leishmania spp.: Current Progress
3. A Snapshot of Antileishmanial Peptides from the Literature
4. Understanding the Primary Structure and Composition of Leishmanicidal Peptides
5. Deeper Insights into the Physicochemical Properties of Antileishmanial Peptides
6. Perspectives and Directions for Future Research on Antileishmanial Peptides
7. Concluding Remarks
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Burza, S.; Croft, S.L.; Boelaert, M. Leishmaniasis. Lancet 2018, 392, 951–970. [Google Scholar] [CrossRef]
- Matlashewski, G.; Pandey, R.; Das, V.; Das, P. One more death from visceral leishmaniasis has gone by unnoticed. What can be done? PLoS Negl. Trop. Dis. 2013, 7, e2082. [Google Scholar] [CrossRef] [Green Version]
- WHO. Leishmaniasis. Available online: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (accessed on 28 January 2021).
- Hewawasam, C.; Weerakoon, H.S.; Thilakan, V.; Lelwala, T.; Prasanka, K.; Rathnayaka, A.S.; Gamage, S.; Agampodi, S. Is leishmaniasis adequately notified in Sri Lanka? A survey among doctors from an endemic district, Sri Lanka. BMC Public Health 2020, 20, 913. [Google Scholar] [CrossRef] [PubMed]
- Steverding, D. The history of leishmaniasis. Parasites Vectors 2017, 10, 82. [Google Scholar] [CrossRef] [Green Version]
- Melby, P.; Travi, B.; Osorio, E.Y. Leishmania. In Encyclopedia of Microbiology; Elsevier: Amsterdam, The Netherlands, 2019; pp. 769–779. [Google Scholar]
- Gluenz, E.; Ginger, M.L.; McKean, P.G. Flagellum assembly and function during the Leishmania life cycle. Curr. Opin. Microbiol. 2010, 13, 473–479. [Google Scholar] [CrossRef] [PubMed]
- Piscopo, T.V.; Mallia Azzopardi, C. Leishmaniasis. Postgrad. Med. J. 2007, 83, 649–657. [Google Scholar] [CrossRef] [Green Version]
- Alvar, J.; Arana, B.I. Appraisal of Leishmaniasis Chemotherapy, Current Status and Pipeline StrategiesChapter 1 Leishmaniasis, Impact and Therapeutic Needs. In Drug Discovery for Leishmaniasis; 2017; pp. 1–23. [Google Scholar] [CrossRef]
- Sangshetti, J.N.; Khan, F.A.K.; Kulkarni, A.A.; Arote, R.; Patil, R.H. Antileishmanial drug discovery: Comprehensive review of the last 10 years. Rsc. Adv. 2015, 5, 32376–32415. [Google Scholar] [CrossRef]
- Fernández, O.L.; Diaz-Toro, Y.; Ovalle, C.; Valderrama, L.; Muvdi, S.; Rodríguez, I.; Gomez, M.A.; Saravia, N.G. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. PLoS Negl. Trop. Dis. 2014, 8, e2871. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hussain, H.; Al-Harrasi, A.; Al-Rawahi, A.; Green, I.R.; Gibbons, S. Fruitful decade for antileishmanial compounds from 2002 to late 2011. Chem. Rev. 2014, 114, 10369–10428. [Google Scholar] [CrossRef]
- Sundar, S.; Chakravarty, J.; Meena, L.P. Leishmaniasis: Treatment, drug resistance and emerging therapies. Expert Opin. Orphan Drugs 2019, 7, 1–10. [Google Scholar] [CrossRef]
- Zahedifard, F.; Rafati, S. Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control. Expert Rev. Anti-Infect. Ther. 2018, 16, 461–469. [Google Scholar] [CrossRef]
- Rafferty, J.; Nagaraj, H.; McCloskey, A.P.; Huwaitat, R.; Porter, S.; Albadr, A.; Laverty, G. Peptide therapeutics and the pharmaceutical industry: Barriers encountered translating from the laboratory to patients. Curr. Med. Chem. 2016, 23, 4231–4259. [Google Scholar] [CrossRef]
- Marqus, S.; Pirogova, E.; Piva, T.J. Evaluation of the use of therapeutic peptides for cancer treatment. J. Biomed. Sci. 2017, 24, 21. [Google Scholar] [CrossRef] [Green Version]
- Costa, F.; Teixeira, C.; Gomes, P.; Martins, M.C.L. Clinical application of AMPs. Adv. Exp. Med. Biol. 2019, 1117, 281–298. [Google Scholar] [CrossRef]
- Almeida, J.R.; Mendes, B.; Lancellotti, M.; Marangoni, S.; Vale, N.; Passos, Ó.; Ramos, M.J.; Fernandes, P.A.; Gomes, P.; Da Silva, S.L. A novel synthetic peptide inspired on Lys49 phospholipase A2 from Crotalus oreganus abyssus snake venom active against multidrug-resistant clinical isolates. Eur. J. Med. Chem. 2018, 149, 248–256. [Google Scholar] [CrossRef]
- Cobb, S.L.; Denny, P.W. Antimicrobial peptides for leishmaniasis. Curr. Opin. Investig. Drugs 2010, 11, 868–875. [Google Scholar]
- Felício, M.R.; Silva, O.N.; Gonçalves, S.; Santos, N.C.; Franco, O.L. Peptides with dual antimicrobial and anticancer activities. Front. Chem. 2017, 5, 5. [Google Scholar] [CrossRef] [Green Version]
- Gaspar, D.; Veiga, A.S.; Castanho, M.A. From antimicrobial to anticancer peptides. A review. Front. Microbiol. 2013, 4, 294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fernández de Ullivarri, M.; Arbulu, S.; Garcia-Gutierrez, E.; Cotter, P.D. Antifungal Peptides as Therapeutic Agents. Front. Cell. Infect. Microbiol. 2020, 10, 105. [Google Scholar] [CrossRef]
- Almeida, J.R.; Palacios, A.L.; Patiño, R.S.; Mendes, B.; Teixeira, C.A.; Gomes, P.; da Silva, S.L. Harnessing snake venom phospholipases A2 to novel approaches for overcoming antibiotic resistance. Drug Dev. Res. 2019, 80, 68–85. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mahlapuu, M.; Håkansson, J.; Ringstad, L.; Björn, C. Antimicrobial peptides: An emerging category of therapeutic agents. Front. Cell. Infect. Microbiol. 2016, 6, 194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Torrent, M.; Pulido, D.; Rivas, L.; Andreu, D. Antimicrobial peptide action on parasites. Curr. Drug Targets 2012, 13, 1138–1147. [Google Scholar] [CrossRef]
- Marr, A.; Cen, S.; Hancock, R.; McMaster, W. Identification of synthetic and natural host defense peptides with leishmanicidal activity. Antimicrob. Agents Chemother. 2016, 60, 2484–2491. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luque-Ortega, J.R.; Rivas, L. Characterization of the leishmanicidal activity of antimicrobial peptides. In Antimicrobial Peptides; Springer: Berlin/Heidelberg, Germany, 2010; pp. 393–420. [Google Scholar]
- Torres-Guerrero, E.; Quintanilla-Cedillo, M.R.; Ruiz-Esmenjaud, J.; Arenas, R. Leishmaniasis: A review. F1000Research 2017, 6. [Google Scholar] [CrossRef]
- Mehta, D.; Anand, P.; Kumar, V.; Joshi, A.; Mathur, D.; Singh, S.; Tuknait, A.; Chaudhary, K.; Gautam, S.K.; Gautam, A. ParaPep: A web resource for experimentally validated antiparasitic peptide sequences and their structures. Database 2014. [Google Scholar] [CrossRef]
- Hernandez, C.; Mor, A.; Dagger, F.; Nicolas, P.; Hernandez, A.; Benedetti, E.; Dunia, I. Functional and structural damage in Leishmania mexicana exposed to the cationic peptide dermaseptin. Eur. J. Cell Biol. 1992, 59, 414–424. [Google Scholar]
- Maróti, G.; Kereszt, A.; Kondorosi, E.; Mergaert, P. Natural roles of antimicrobial peptides in microbes, plants and animals. Res. Microbiol. 2011, 162, 363–374. [Google Scholar] [CrossRef] [PubMed]
- Azmi, F.; Skwarczynski, M.; Toth, I. Towards the development of synthetic antibiotics: Designs inspired by natural antimicrobial peptides. Curr. Med. Chem. 2016, 23, 4610–4624. [Google Scholar] [CrossRef] [PubMed]
- Liu, S.; Fan, L.; Sun, J.; Lao, X.; Zheng, H. Computational resources and tools for antimicrobial peptides. J. Pept. Sci. 2017, 23, 4–12. [Google Scholar] [CrossRef] [PubMed]
- Haney, E.F.; Mansour, S.C.; Hancock, R.E. Antimicrobial peptides: An introduction. In Antimicrobial Peptides; Springer: Berlin/Heidelberg, Germany, 2017; pp. 3–22. [Google Scholar]
- Pirogova, E.; Istivan, T.; Gan, E.; Cosic, I. Advances in methods for therapeutic peptide discovery, design and development. Curr. Pharm. Biotechnol. 2011, 12, 1117–1127. [Google Scholar] [CrossRef]
- Mangoni, M.L.; Saugar, J.M.; Dellisanti, M.; Barra, D.; Simmaco, M.; Rivas, L. Temporins, small antimicrobial peptides with leishmanicidal activity. J. Biol. Chem. 2005, 280, 984–990. [Google Scholar] [CrossRef] [Green Version]
- Savoia, D.; Guerrini, R.; Marzola, E.; Salvadori, S. Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorgan. Med. Chem. 2008, 16, 8205–8209. [Google Scholar] [CrossRef] [Green Version]
- Dias-Achirica, P.; Ubach, J.; Guinea, A.; Andreu, D.; Rivas, L. The plasma membrane of Leishmania donovani promastigotes is the main target for CA (1–8) M (1–18), a synthetic cecropin A–melittin hybrid peptide. Biochem. J. 1998, 330, 453–460. [Google Scholar] [CrossRef] [PubMed]
- Raja, Z.; André, S.; Abbassi, F.; Humblot, V.; Lequin, O.; Bouceba, T.; Correia, I.; Casale, S.; Foulon, T.; Sereno, D. Insight into the mechanism of action of temporin-SHa, a new broad-spectrum antiparasitic and antibacterial agent. PLoS ONE 2017, 12, e0174024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chicharro, C.; Granata, C.; Lozano, R.; Andreu, D.; Rivas, L. N-terminal fatty acid substitution increases the leishmanicidal activity of CA (1–7) M (2–9), a cecropin-melittin hybrid peptide. Antimicrob. Agents Chemother. 2001, 45, 2441–2449. [Google Scholar] [CrossRef] [Green Version]
- Guerrero, E.; Saugar, J.M.; Matsuzaki, K.; Rivas, L. Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob. Agents Chemother. 2004, 48, 2980–2986. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mendes, B.; Almeida, J.R.; Vale, N.; Gomes, P.; Gadelha, F.R.; Da Silva, S.L.; Miguel, D.C. Potential use of 13-mer peptides based on phospholipase and oligoarginine as leishmanicidal agents. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2019, 226, 108612. [Google Scholar] [CrossRef]
- Katz, S.; Barbiéri, C.L.; Soler, F.P.; Soares, A.M.; Chavantes, M.C.; Zamuner, S.R. Effect of isolated proteins from Crotalus durissus terrificus venom on Leishmania (Leishmania) amazonensis-infected macrophages. Protein Pept. Lett. 2020, 27, 718–724. [Google Scholar] [CrossRef]
- König, E.; Bininda-Emonds, O.R. Evidence for convergent evolution in the antimicrobial peptide system in anuran amphibians. Peptides 2011, 32, 20–25. [Google Scholar] [CrossRef]
- Rollins-Smith, L.A. The role of amphibian antimicrobial peptides in protection of amphibians from pathogens linked to global amphibian declines. Biochim. Biophys. Acta (BBA)-Biomembr. 2009, 1788, 1593–1599. [Google Scholar] [CrossRef] [Green Version]
- Mendes, B.; Proaño-Bolaños, C.; Gadelha, F.R.; Almeida, J.R.; Miguel, D.C. Cruzioseptins, antibacterial peptides from Cruziohyla calcarifer skin, as promising leishmanicidal agents. Pathog. Dis. 2020, 78, ftaa053. [Google Scholar] [CrossRef]
- Proaño-Bolaños, C.; Blasco-Zúñiga, A.; Almeida, J.R.; Wang, L.; Llumiquinga, M.A.; Rivera, M.; Zhou, M.; Chen, T.; Shaw, C. Unravelling the skin secretion peptides of the gliding leaf frog, Agalychnis spurrelli (Hylidae). Biomolecules 2019, 9, 667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vouldoukis, I.; Shai, Y.; Nicolas, P.; Mor, A. Broad spectrum antibiotic activity of skin-PYY. FEBS Lett. 1996, 380, 237–240. [Google Scholar] [CrossRef] [Green Version]
- Oliveira, M.; Gomes-Alves, A.G.; Sousa, C.; Mirta Marani, M.; Plácido, A.; Vale, N.; Delerue-Matos, C.; Gameiro, P.; Kückelhaus, S.A.; Tomas, A.M. Ocellatin-PT antimicrobial peptides: High-resolution microscopy studies in antileishmania models and interactions with mimetic membrane systems. Biopolymers 2016, 105, 873–886. [Google Scholar] [CrossRef] [Green Version]
- Eggimann, G.A.; Sweeney, K.; Bolt, H.L.; Rozatian, N.; Cobb, S.L.; Denny, P.W. The role of phosphoglycans in the susceptibility of Leishmania mexicana to the temporin family of anti-microbial peptides. Molecules 2015, 20, 2775–2785. [Google Scholar] [CrossRef] [Green Version]
- Hillesland, H.; Read, A.; Subhadra, B.; Hurwitz, I.; McKelvey, R.; Ghosh, K.; Das, P.; Durvasula, R. Identification of aerobic gut bacteria from the kala azar vector, Phlebotomus argentipes: A platform for potential paratransgenic manipulation of sand flies. Am. J. Trop. Med. Hyg. 2008, 79, 881–886. [Google Scholar] [CrossRef] [Green Version]
- Abassi, R.; Akhlaghi, M.; Oshaghi, M.; Akhavan, A.; Yaghoobi-Ershadi, M.; Bakhtiary, R. Dynamics and fitness cost of genetically engineered Entrobacter cloacae expressing defensin for paratransgenesis in Phlebotomus papatasi. J. Bacteriol. Parasitol. 2019, 10, 349. [Google Scholar] [CrossRef] [Green Version]
- Pigott, D.M.; Bhatt, S.; Golding, N.; Duda, K.A.; Battle, K.E.; Brady, O.J.; Messina, J.P.; Balard, Y.; Bastien, P.; Pratlong, F. Global distribution maps of the leishmaniases. Elife 2014, 3, e02851. [Google Scholar] [CrossRef]
- Abbassi, F.; Raja, Z.; Oury, B.; Gazanion, E.; Piesse, C.; Sereno, D.; Nicolas, P.; Foulon, T.; Ladram, A. Antibacterial and leishmanicidal activities of temporin-SHd, a 17-residue long membrane-damaging peptide. Biochimie 2013, 95, 388–399. [Google Scholar] [CrossRef] [PubMed]
- Cao, L.; Jiang, W.; Cao, S.; Zhao, P.; Liu, J.; Dong, H.; Guo, Y.; Liu, Q.; Gong, P. In vitro leishmanicidal activity of antimicrobial peptide KDEL against Leishmania tarentolae. Acta Biochim. Biophys. Sin. 2019, 51, 1286–1292. [Google Scholar] [CrossRef]
- Bera, A.; Singh, S.; Nagaraj, R.; Vaidya, T. Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol. Biochem. Parasitol. 2003, 127, 23–35. [Google Scholar] [CrossRef]
- Rončević, T.; Puizina, J.; Tossi, A. Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era? Int. J. Mol. Sci. 2019, 20, 5713. [Google Scholar] [CrossRef] [Green Version]
- Browne, K.; Chakraborty, S.; Chen, R.; Willcox, M.D.; Black, D.S.; Walsh, W.R.; Kumar, N. A new era of antibiotics: The clinical potential of antimicrobial peptides. Int. J. Mol. Sci. 2020, 21, 7047. [Google Scholar] [CrossRef]
- Lazzaro, B.P.; Zasloff, M.; Rolff, J. Antimicrobial peptides: Application informed by evolution. Science 2020, 368, aau5480. [Google Scholar] [CrossRef]
- Lynn, M.A.; Kindrachuk, J.; Marr, A.K.; Jenssen, H.; Panté, N.; Elliott, M.R.; Napper, S.; Hancock, R.E.; McMaster, W.R. Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: Role of leishmanolysin in parasite survival. PLoS Negl. Trop. Dis. 2011, 5, e1141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pérez-Cordero, J.J.; Lozano, J.M.; Cortés, J.; Delgado, G. Leishmanicidal activity of synthetic antimicrobial peptides in an infection model with human dendritic cells. Peptides 2011, 32, 683–690. [Google Scholar] [CrossRef] [PubMed]
- Alberola, J.; Rodriguez, A.; Francino, O.; Roura, X.; Rivas, L.; Andreu, D. Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob. Agents Chemother. 2004, 48, 641–643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mukherjee, S.; Ukil, A.; Das, P.K. Immunomodulatory peptide from cystatin, a natural cysteine protease inhibitor, against leishmaniasis as a model macrophage disease. Antimicrob. Agents Chemother. 2007, 51, 1700–1707. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Erfe, M.C.B.; David, C.V.; Huang, C.; Lu, V.; Maretti-Mira, A.C.; Haskell, J.; Bruhn, K.W.; Yeaman, M.R.; Craft, N. Efficacy of synthetic peptides RP-1 and AA-RP-1 against Leishmania species in vitro and in vivo. Antimicrob. Agents Chemother. 2012, 56, 658–665. [Google Scholar] [CrossRef]
- Campos-Salinas, J.; Caro, M.; Cavazzuti, A.; Forte-Lago, I.; Beverley, S.M.; O’Valle, F.; Gonzalez-Rey, E. Protective role of the neuropeptide urocortin II against experimental sepsis and leishmaniasis by direct killing of pathogens. J. Immunol. 2013, 191, 6040–6051. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Campos-Salinas, J.; Cavazzuti, A.; O’Valle, F.; Forte-Lago, I.; Caro, M.; Beverley, S.M.; Delgado, M.; Gonzalez-Rey, E. Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens. J. Biol. Chem. 2014, 289, 14583–14599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abdossamadi, Z.; Seyed, N.; Zahedifard, F.; Taheri, T.; Taslimi, Y.; Montakhab-Yeganeh, H.; Badirzadeh, A.; Vasei, M.; Gharibzadeh, S.; Rafati, S. Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice. PLoS Negl. Trop. Dis. 2017, 11, e0006123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marr, A.K.; McGwire, B.S.; McMaster, W.R. Modes of action of Leishmanicidal antimicrobial peptides. Future Microbiol. 2012, 7, 1047–1059. [Google Scholar] [CrossRef]
- Abdossamadi, Z.; Taheri, T.; Seyed, N.; Montakhab-Yeganeh, H.; Zahedifard, F.; Taslimi, Y.; Habibzadeh, S.; Gholami, E.; Gharibzadeh, S.; Rafati, S. Live Leishmania tarentolae secreting HNP1 as an immunotherapeutic tool against Leishmania infection in BALB/c mice. Immunotherapy 2017, 9, 1089–1102. [Google Scholar] [CrossRef]
- Luque-Ortega, J.R.; Beatriz, G.; Hornillos, V.; Bart, J.-M.; Rueda, C.; Navarro, M.; Amat-Guerri, F.; Acuña, A.U.; Andreu, D.; Rivas, L. Defeating Leishmania resistance to miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: A proof of mechanism for trypanosomatid chemotherapy. J. Control. Release 2012, 161, 835–842. [Google Scholar] [CrossRef] [PubMed]
- Defaus, S.; Gallo, M.; Abengózar, M.A.; Rivas, L.; Andreu Martínez, D. A synthetic strategy for conjugation of paromomycin to cell-penetrating TAT (48-60) for delivery and visualization into Leishmania parasites. Int. J. Pept. 2017, 2017, 4213037. [Google Scholar] [CrossRef] [Green Version]
- Wang, G.; Li, X.; Wang, Z. APD3: The antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 2016, 44, D1087–D1093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Usmani, S.S.; Bedi, G.; Samuel, J.S.; Singh, S.; Kalra, S.; Kumar, P.; Ahuja, A.A.; Sharma, M.; Gautam, A.; Raghava, G.P. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 2017, 12, e0181748. [Google Scholar] [CrossRef] [Green Version]
- Guimaraes, A.B.; Costa, F.J.Q.; Junior, O.R.P.; Fontes, W.; Castro, M.S. The amazing world of peptide engineering: The example of antimicrobial peptides from frogs and their analogues. Protein Pept. Lett. 2016, 23, 722–737. [Google Scholar] [CrossRef]
- Ebrahimzade, E.; Mohebali, M.; Shayan, P.; Mohammadi-Yeganeh, S.; Moghaddam, M.M.; Elikaee, S.; Akhoundi, B.; Sharifi-Yazdi, M.K. Investigation of the antimicrobial activity of a short cationic peptide against promastigote and amastigote forms of Leishmania major (MHRO/IR/75/ER): An in vitro study. Exp. Parasitol. 2019, 196, 48–54. [Google Scholar] [CrossRef]
- Zahedifard, F.; Lee, H.; No, J.H.; Salimi, M.; Seyed, N.; Asoodeh, A.; Rafati, S. Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite. Exp. Parasitol. 2020, 209, 107823. [Google Scholar] [CrossRef]
- Cruz, L.J.; Luque-Ortega, J.R.; Rivas, L.; Albericio, F. Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents. Mol. Pharm. 2009, 6, 813–824. [Google Scholar] [CrossRef] [PubMed]
- Chaves, R.X.; Quelemes, P.V.; Leite, L.M.; Aquino, D.S.A.; Amorim, L.V.; Rodrigues, K.A.F.; Campelo, Y.D.M.; Veras, L.M.C.; Bemquerer, M.P.; Ramos-Jesus, J. Antileishmanial and immunomodulatory effects of Dermaseptin-01, a promising peptide against Leishmania amazonensis. Curr. Bioact. Compd. 2017, 13, 305–311. [Google Scholar] [CrossRef]
- Haines, L.R.; Thomas, J.M.; Jackson, A.M.; Eyford, B.A.; Razavi, M.; Watson, C.N.; Gowen, B.; Hancock, R.E.; Pearson, T.W. Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18. PLoS Negl. Trop. Dis. 2009, 3, e373. [Google Scholar] [CrossRef] [PubMed]
- Pinto, E.G.; Pimenta, D.C.; Antoniazzi, M.M.; Jared, C.; Tempone, A.G. Antimicrobial peptides isolated from Phyllomedusa nordestina (Amphibia) alter the permeability of plasma membrane of Leishmania and Trypanosoma cruzi. Exp. Parasitol. 2013, 135, 655–660. [Google Scholar] [CrossRef] [PubMed]
- Sardar, A.; Das, S.; Agnihorti, S.; Kumar, M.; Ghosh, A.; Abhishek, K.; Kumar, A.; Purkait, B.; Ansari, M.; Das, P. Spinigerin induces apoptotic like cell death in a caspase independent manner in Leishmania donovani. Exp. Parasitol. 2013, 135, 715–725. [Google Scholar] [CrossRef]
- Lien, S.; Lowman, H.B. Therapeutic peptides. Trends Biotechnol. 2003, 21, 556–562. [Google Scholar] [CrossRef]
- Löfgren, S.; Miletti, L.; Steindel, M.; Bachere, E.; Barracco, M. Trypanocidal and leishmanicidal activities of different antimicrobial peptides (AMPs) isolated from aquatic animals. Exp. Parasitol. 2008, 118, 197–202. [Google Scholar] [CrossRef]
- McGwire, B.S.; Kulkarni, M.M. Interactions of antimicrobial peptides with Leishmania and trypanosomes and their functional role in host parasitism. Exp. Parasitol. 2010, 126, 397–405. [Google Scholar] [CrossRef]
- Deslouches, B.; Hasek, M.L.; Craigo, J.K.; Steckbeck, J.D.; Montelaro, R.C. Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine. J. Med. Microbiol. 2016, 65, 554. [Google Scholar] [CrossRef]
- Ojeda, P.G.; Henriques, S.T.; Pan, Y.; Nicolazzo, J.A.; Craik, D.J.; Wang, C.K. Lysine to arginine mutagenesis of chlorotoxin enhances its cellular uptake. Pept. Sci. 2017, 108, e23025. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Y.; Guarnieri, M.T.; Vasil, A.I.; Vasil, M.L.; Mant, C.T.; Hodges, R.S. Role of peptide hydrophobicity in the mechanism of action of α-helical antimicrobial peptides. Antimicrob. Agents Chemother. 2007, 51, 1398–1406. [Google Scholar] [CrossRef] [Green Version]
- Sabiá Júnior, E.F.; Menezes, L.F.S.; de Araújo, I.F.S.; Schwartz, E.F. Natural occurrence in venomous arthropods of antimicrobial peptides active against protozoan parasites. Toxins 2019, 11, 563. [Google Scholar] [CrossRef] [Green Version]
- Konno, K.; Rangel, M.; Oliveira, J.S.; dos Santos Cabrera, M.P.; Fontana, R.; Hirata, I.Y.; Hide, I.; Nakata, Y.; Mori, K.; Kawano, M. Decoralin, a novel linear cationic α-helical peptide from the venom of the solitary eumenine wasp Oreumenes decoratus. Peptides 2007, 28, 2320–2327. [Google Scholar] [CrossRef]
- Asthana, N.; Yadav, S.P.; Ghosh, J.K. Dissection of antibacterial and toxic activity of Melittin a leucine zipper motif plays a crucial role in determining its hemolytic activity but not antibacterial activity. J. Biol. Chem. 2004, 279, 55042–55050. [Google Scholar] [CrossRef] [Green Version]
- Ahmad, A.; Azmi, S.; Srivastava, R.M.; Srivastava, S.; Pandey, B.K.; Saxena, R.; Bajpai, V.K.; Ghosh, J.K. Design of nontoxic analogues of cathelicidin-derived bovine antimicrobial peptide BMAP-27: The role of leucine as well as phenylalanine zipper sequences in determining its toxicity. Biochemistry 2009, 48, 10905–10917. [Google Scholar] [CrossRef] [PubMed]
- Tossi, A.; Sandri, L.; Giangaspero, A. Amphipathic, α-helical antimicrobial peptides. Pept. Sci. 2000, 55, 4–30. [Google Scholar] [CrossRef]
- Bahar, A.A.; Ren, D. Antimicrobial peptides. Pharmaceuticals 2013, 6, 1543–1575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Radzishevsky, I.S.; Rotem, S.; Zaknoon, F.; Gaidukov, L.; Dagan, A.; Mor, A. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob. Agents Chemother. 2005, 49, 2412–2420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tennessen, J. Molecular evolution of animal antimicrobial peptides: Widespread moderate positive selection. J. Evol. Biol. 2005, 18, 1387–1394. [Google Scholar] [CrossRef]
- Osorio, D.; Rondón-Villarrea, P.; Torres, R. Peptides: A package for data mining of antimicrobial peptides. R J. 2015, 7. [Google Scholar] [CrossRef]
- Lee, H.-T.; Lee, C.-C.; Yang, J.-R.; Lai, J.Z.; Chang, K.Y. A large-scale structural classification of antimicrobial peptides. Biomed. Res. Int. 2015. [Google Scholar] [CrossRef]
- Waghu, F.H.; Barai, R.S.; Gurung, P.; Idicula-Thomas, S. CAMPR3: A database on sequences, structures and signatures of antimicrobial peptides. Nucleic Acids Res. 2016, 44, D1094–D1097. [Google Scholar] [CrossRef] [Green Version]
- Wang, C.-K.; Shih, L.-Y.; Chang, K.Y. Large-scale analysis of antimicrobial activities in relation to amphipathicity and charge reveals novel characterization of antimicrobial peptides. Molecules 2017, 22, 2037. [Google Scholar] [CrossRef] [Green Version]
- PAHO. Leishmaniasis. Available online: https://www.paho.org/es/temas/leishmaniasis (accessed on 28 January 2021).
- Ghatee, M.A.; Taylor, W.R.; Karamian, M. The geographical distribution of cutaneous leishmaniasis causative agents in Iran and its neighboring countries, a review. Front. Public Health 2020, 8, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rossi, M.; Fasel, N. How to master the host immune system? Leishmania parasites have the solutions! Int. Immunol. 2018, 30, 103–111. [Google Scholar] [PubMed] [Green Version]
- Boussoffara, T.; Boubaker, M.S.; Ahmed, M.B.; Mokni, M.; Guizani, I.; Salah, A.B.; Louzir, H. Histological and immunological differences between zoonotic cutaneous leishmaniasis due to Leishmania major and sporadic cutaneous leishmaniasis due to Leishmania infantum. Parasite 2019, 26. [Google Scholar] [CrossRef] [Green Version]
- Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: Science and market. Drug Discov. Today 2010, 15, 40–56. [Google Scholar] [CrossRef]
- Barreto-Santamaría, A.; Patarroyo, M.E.; Curtidor, H. Designing and optimizing new antimicrobial peptides: All targets are not the same. Crit. Rev. Clin. Lab. Sci. 2019, 56, 351–373. [Google Scholar] [CrossRef]
- Ruiz-Santaquiteria, M.; Sánchez-Murcia, P.A.; Toro, M.A.; de Lucio, H.; Gutiérrez, K.J.; de Castro, S.; Carneiro, F.A.; Gago, F.; Jiménez-Ruiz, A.; Camarasa, M.-J. First example of peptides targeting the dimer interface of Leishmania infantum trypanothione reductase with potent in vitro antileishmanial activity. Eur. J. Med. Chem. 2017, 135, 49–59. [Google Scholar] [CrossRef] [PubMed]
- Bates, P.A. Revising Leishmania’s life cycle. Nat. Microbiol. 2018, 3, 529–530. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kückelhaus, S.A.; Aquino, D.S.A.d.; Borges, T.K.; Moreira, D.C.; Leite, L.d.M.; Muniz-Junqueira, M.I.; Kückelhaus, C.S.; Romero, G.A.S.; Prates, M.V.; Bloch, C. Phylloseptin-1 is Leishmanicidal for Amastigotes of Leishmania amazonensis Inside Infected Macrophages. Int. J. Environ. Res. Public Health 2020, 17, 4856. [Google Scholar] [CrossRef]
- Beard, C.B.; Durvasula, R.V.; Richards, F.F. Bacterial symbiosis in arthropods and the control of disease transmission. Emerg. Infect. Dis. 1998, 4, 581. [Google Scholar] [CrossRef] [PubMed]
- WHO. WHO Takes a Position on Genetically Modified Mosquitoes. Available online: https://www.who.int/news/item/14-10-2020-who-takes-a-position-on-genetically-modified-mosquitoes (accessed on 28 January 2021).
- Carter, V.; Hurd, H. Choosing anti-Plasmodium molecules for genetically modifying mosquitoes: Focus on peptides. Trends Parasitol. 2010, 26, 582–590. [Google Scholar] [CrossRef] [PubMed]
- Wijerathna, T.; Gunathunga, S.; Gunathilaka, N. Recent developments and future directions in the paratransgenesis based control of Leishmania transmission. Biol. Control 2020, 145, 104260. [Google Scholar] [CrossRef]
- Yamamoto, D.; Nagumo, H.; Yoshida, S. Flying vaccinator; a transgenic mosquito delivers a Leishmania vaccine via blood feeding. Insect Mol. Biol. 2010, 19, 391–398. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Robles-Loaiza, A.A.; Pinos-Tamayo, E.A.; Mendes, B.; Teixeira, C.; Alves, C.; Gomes, P.; Almeida, J.R. Peptides to Tackle Leishmaniasis: Current Status and Future Directions. Int. J. Mol. Sci. 2021, 22, 4400. https://doi.org/10.3390/ijms22094400
Robles-Loaiza AA, Pinos-Tamayo EA, Mendes B, Teixeira C, Alves C, Gomes P, Almeida JR. Peptides to Tackle Leishmaniasis: Current Status and Future Directions. International Journal of Molecular Sciences. 2021; 22(9):4400. https://doi.org/10.3390/ijms22094400
Chicago/Turabian StyleRobles-Loaiza, Alberto A., Edgar A. Pinos-Tamayo, Bruno Mendes, Cátia Teixeira, Cláudia Alves, Paula Gomes, and José R. Almeida. 2021. "Peptides to Tackle Leishmaniasis: Current Status and Future Directions" International Journal of Molecular Sciences 22, no. 9: 4400. https://doi.org/10.3390/ijms22094400